Targeting the disordered N-terminal domain of androgen receptor. Novel inhibitors tackling biomolecular condensation to treat late stage prostate cancer
[eng] Drug discovery is the process by which new drugs are found and developed into the market. Given the scope of this thesis, the term “drug” will refer to small molecules and the term “target” to proteins, otherwise noted. Currently, most drug discovery strategies rely on the resolved three-dimen...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Estado: | Versión publicada |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universidad de Barcelona |
| Repositorio: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/196480 |
| Acceso en línea: | https://hdl.handle.net/2445/196480 http://hdl.handle.net/10803/688018 |
| Access Level: | acceso abierto |
| Palabra clave: | Química orgànica Andrògens Proteïnes Biomolècules Càncer de pròstata Organic chemistry Androgens Proteins Biomolecules Prostate cancer |
| Sumario: | [eng] Drug discovery is the process by which new drugs are found and developed into the market. Given the scope of this thesis, the term “drug” will refer to small molecules and the term “target” to proteins, otherwise noted. Currently, most drug discovery strategies rely on the resolved three-dimensional structure of the target. Structure-based drug discovery (SBDD) is advantageous as it accelerates and lowers the cost of the drug discovery process. However, the essential requisite for SBDD, the prior knowledge of the target protein structure, has narrowed the types of proteins in drug discovery programs to globular proteins. It is estimated that 33-50% of our proteome is intrinsically disordered. Intrinsically disordered proteins (IDPs) and protein regions (IDRs) do not spontaneously fold into a stable secondary and tertiary structure in their native state yet are functionally active. IDPs have long been considered undruggable as their lack of a stable tertiary structure impedes the application of SBDD. Nevertheless, IDPs participate in many physiological processes, as well as in diseases. Hence finding new approaches to target IDPs is crucial to expand the druggable proteome and fill unmet needs across diseases in which disorder plays a role. |
|---|